Adly Yacoub

Assiut University — Egypt

Biochemistry, Genetics and Molecular Biology · Life Sciences

51h-index6.9kcitations153works0.72yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Virus-based gene therapy research(20), Endoplasmic Reticulum Stress and Disease(20), Cell death mechanisms and regulation(18), Cancer-related Molecular Pathways(14), Sphingolipid Metabolism and Signaling(14)

Publications153 total

Systematic Review and Meta-analysis of Targeted Muscle Reinnervation and Regenerative Peripheral Nerve Interface for Post-amputation Pain (P5-7.004)
Neurology·2025
Whole exome sequencing revealed ultra-rare genetic variations in juvenile myoclonic epilepsy
Neurological Sciences·2024· 2 cited
Retraction Notice to: Inhibition of Multiple Protective Signaling Pathways and Ad.5/3 Delivery Enhances mda-7/IL-24 Therapy of Malignant Glioma
Molecular Therapy·2024Open Access
Data from Mitogen-activated protein kinase kinase 1/2 inhibitors and 17-allylamino-17-demethoxygeldanamycin synergize to kill human gastrointestinal tumor cells <i>in vitro</i> via suppression of c-FLIP-s levels and activation of CD95
2023Open Access
Data from MDA-7/IL-24–induced cell killing in malignant renal carcinoma cells occurs by a ceramide/CD95/PERK–dependent mechanism
2023Open Access
Supplementary Data from 17-Allylamino-17-Demethoxygeldanamycin and MEK1/2 Inhibitors Kill GI Tumor Cells via Ca<sup>2+</sup>-Dependent Suppression of GRP78/BiP and Induction of Ceramide and Reactive Oxygen Species
2023Open Access
Data from Vorinostat and Sorafenib Synergistically Kill Tumor Cells via FLIP Suppression and CD95 Activation
2023Open Access
Data from Mitogen-activated protein kinase kinase 1/2 inhibitors and 17-allylamino-17-demethoxygeldanamycin synergize to kill human gastrointestinal tumor cells <i>in vitro</i> via suppression of c-FLIP-s levels and activation of CD95
2023Open Access
Data from Sorafenib Activates CD95 and Promotes Autophagy and Cell Death via Src Family Kinases in Gastrointestinal Tumor Cells
2023Open Access
Data from 17-Allylamino-17-Demethoxygeldanamycin and MEK1/2 Inhibitors Kill GI Tumor Cells via Ca<sup>2+</sup>-Dependent Suppression of GRP78/BiP and Induction of Ceramide and Reactive Oxygen Species
2023Open Access
Supplementary Material from Mitogen-activated protein kinase kinase 1/2 inhibitors and 17-allylamino-17-demethoxygeldanamycin synergize to kill human gastrointestinal tumor cells <i>in vitro</i> via suppression of c-FLIP-s levels and activation of CD95
2023Open Access
Supplementary Figures S1-S18 from Vorinostat and Sorafenib Synergistically Kill Tumor Cells via FLIP Suppression and CD95 Activation
2023Open Access
Data from Vorinostat and Sorafenib Synergistically Kill Tumor Cells via FLIP Suppression and CD95 Activation
2023Open Access
Supplementary Fig. from MDA-7/IL-24–induced cell killing in malignant renal carcinoma cells occurs by a ceramide/CD95/PERK–dependent mechanism
2023Open Access
Data from 17-Allylamino-17-Demethoxygeldanamycin and MEK1/2 Inhibitors Kill GI Tumor Cells via Ca<sup>2+</sup>-Dependent Suppression of GRP78/BiP and Induction of Ceramide and Reactive Oxygen Species
2023Open Access
Supplementary Data from Sorafenib Activates CD95 and Promotes Autophagy and Cell Death via Src Family Kinases in Gastrointestinal Tumor Cells
2023Open Access
Supplementary Figures S1-S18 from Vorinostat and Sorafenib Synergistically Kill Tumor Cells via FLIP Suppression and CD95 Activation
2023Open Access
Supplementary Data from 17-Allylamino-17-Demethoxygeldanamycin and MEK1/2 Inhibitors Kill GI Tumor Cells via Ca<sup>2+</sup>-Dependent Suppression of GRP78/BiP and Induction of Ceramide and Reactive Oxygen Species
2023Open Access
Supplementary Material from Mitogen-activated protein kinase kinase 1/2 inhibitors and 17-allylamino-17-demethoxygeldanamycin synergize to kill human gastrointestinal tumor cells <i>in vitro</i> via suppression of c-FLIP-s levels and activation of CD95
2023Open Access
Supplementary Fig. from MDA-7/IL-24–induced cell killing in malignant renal carcinoma cells occurs by a ceramide/CD95/PERK–dependent mechanism
2023Open Access
page 1 of 8Next →

Frequent Co-authors

Paul Dent(32), Paul B. Fisher(28), Steven Grant(21), Devanand Sarkar(16), David T. Curiel(13), Clint Mitchell(13), Margaret A. Park(13), Michael P. Hagan(11), Irina V. Lebedeva(11), Paul Dent(10), Mohamed Rahmani(10), Steven Grant(9), Rahul V. Gopalkrishnan(8), Hossein A. Hamed(7), Moira Sauane(6), Robert McKinstry(6), Liang Qiao(6), Rupesh Dash(6), Sarah Spiegel(6), Pankaj Gupta(6)